Although the majority of clinical benefits from lapatinib were achieved in patients with HER2-positive breast cancers, treatment with lapatinib for TNBC or HER2-negative patients continues to be of interest due to its anti-EGFR activity [8, 9]. The gene discussed is ERBB2; the disease is breast cancer.